Patents by Inventor David Kiewlich

David Kiewlich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for reducing elevated glucose levels
    Patent number: 12703856
    Abstract: Described herein are human transgenic beta cells expressing fugetactic levels of CXCL12 to a subject in need thereof. Also described herein are beta cells comprising a transgene comprising a nucleic acid sequence encoding CXCL12.
    Type: Grant
    Filed: April 9, 2024
    Date of Patent: August 11, 2026
    Assignee: SDF BioPharma, Inc
    Inventors: Gerald Swiss, David Kiewlich
  • Genetically modified stem cells
    Patent number: 12365876
    Abstract: Described herein are human transgenic beta cells expressing fugetactic levels of CXCL12 to a subject in need thereof. Also described herein are beta cells comprising a transgene comprising a nucleic acid sequence encoding CXCL12.
    Type: Grant
    Filed: July 25, 2023
    Date of Patent: July 22, 2025
    Assignee: SDF BioPharma
    Inventors: Gerald F. Swiss, David Kiewlich
  • METHODS FOR REDUCING ELEVATED GLUCOSE LEVELS
    Publication number: 20240360418
    Abstract: Described herein are human transgenic beta cells expressing fugetactic levels of CXCL12 to a subject in need thereof. Also described herein are beta cells comprising a transgene comprising a nucleic acid sequence encoding CXCL12.
    Type: Application
    Filed: April 9, 2024
    Publication date: October 31, 2024
    Inventors: Gerald SWISS, David KIEWLICH
  • Methods for reducing elevated glucose levels
    Patent number: 11981928
    Abstract: Described herein are human transgenic beta cells expressing fugetactic levels of CXCL12 to a subject in need thereof. Also described herein are beta cells comprising a transgene comprising a nucleic acid sequence encoding CXCL12.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: May 14, 2024
    Assignee: SDF BIOPHARMA INC.
    Inventors: Gerald F. Swiss, David Kiewlich
  • GENETICALLY MODIFIED STEM CELLS
    Publication number: 20240150722
    Abstract: Described herein are human transgenic beta cells expressing fugetactic levels of CXCL12 to a subject in need thereof. Also described herein are beta cells comprising a transgene comprising a nucleic acid sequence encoding CXCL12.
    Type: Application
    Filed: July 25, 2023
    Publication date: May 9, 2024
    Inventors: Gerald F. Swiss, David Kiewlich
  • TREATING DIABETES
    Publication number: 20240024371
    Abstract: Described herein are compositions and methods for treating a subject having diabetes comprising administering transgenic beta cells expressing fugetactic levels of CXCL12 to a subject in need thereof. Genetically engineered immune-protected, human beta cells are also described. The disclosed engineered beta cells can be administered to the subject alone or implanted into or with a biocompatible and biodegradable matrix that elutes an effective amount of a fugetactic agent, which is then implanted into the subject.
    Type: Application
    Filed: December 3, 2021
    Publication date: January 25, 2024
    Inventors: Gerald F. SWISS, David KIEWLICH
  • Genetically modified stem cells
    Patent number: 11739298
    Abstract: Described herein are human transgenic beta cells expressing fugetactic levels of CXCL12 to a subject in need thereof. Also described herein are beta cells comprising a transgene comprising a nucleic acid sequence encoding CXCL12.
    Type: Grant
    Filed: November 9, 2021
    Date of Patent: August 29, 2023
    Assignee: SDF BioPharma Inc.
    Inventors: Gerald F. Swiss, David Kiewlich
  • TREATING AUTOIMMUNE DISEASES WITH GENETICALLY MODIFIED CELLS
    Publication number: 20230149511
    Abstract: Described herein are human genetically modified cells or precursors expressing fugetactic levels of a fugetactic agent, e.g. CXCL12, and methods of treating an autoimmune disease in a subject in need thereof. Also described herein are cells or precursors comprising a transgene or other genetic modification for expression of a nucleic acid sequence encoding a fugetactic agent, e.g. CXCL12.
    Type: Application
    Filed: April 9, 2021
    Publication date: May 18, 2023
    Inventors: Lisa HULLE, David KIEWLICH, Joan ROBBINS, Gerald SWISS
  • GENETICALLY MODIFIED STEM CELLS
    Publication number: 20220145262
    Abstract: Described herein are human transgenic beta cells expressing fugetactic levels of CXCL12 to a subject in need thereof. Also described herein are beta cells comprising a transgene comprising a nucleic acid sequence encoding CXCL12.
    Type: Application
    Filed: November 9, 2021
    Publication date: May 12, 2022
    Applicant: SDF BioPharma Inc.
    Inventors: Gerald F. Swiss, David Kiewlich
  • Genetically modified stem cells
    Patent number: 11186827
    Abstract: Described herein are human transgenic beta cells expressing fugetactic levels of CXCL12 to a subject in need thereof. Also described herein are beta cells comprising a transgene comprising a nucleic acid sequence encoding CXCL12.
    Type: Grant
    Filed: April 5, 2021
    Date of Patent: November 30, 2021
    Assignee: SDF BIOPHARMA INC.
    Inventors: Gerald F. Swiss, David Kiewlich
  • GENETICALLY MODIFIED STEM CELLS
    Publication number: 20210355449
    Abstract: Described herein are human transgenic beta cells expressing fugetactic levels of CXCL12 to a subject in need thereof. Also described herein are beta cells comprising a transgene comprising a nucleic acid sequence encoding CXCL12.
    Type: Application
    Filed: April 5, 2021
    Publication date: November 18, 2021
    Applicant: SDF BioPharma Inc.
    Inventors: Gerald F. Swiss, David Kiewlich
  • Genetically modified stem cells
    Patent number: 10982190
    Abstract: Described herein are human transgenic beta cells expressing fugetactic levels of CXCL12 to a subject in need thereof. Also described herein are beta cells comprising a transgene comprising a nucleic acid sequence encoding CXCL12.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: April 20, 2021
    Assignee: SDF BioPharma Inc.
    Inventors: Gerald F. Swiss, David Kiewlich
  • METHODS FOR REDUCING ELEVATED GLUCOSE LEVELS
    Publication number: 20200405772
    Abstract: Described herein are human transgenic beta cells expressing fugetactic levels of CXCL12 to a subject in need thereof. Also described herein are beta cells comprising a transgene comprising a nucleic acid sequence encoding CXCL12.
    Type: Application
    Filed: September 28, 2018
    Publication date: December 31, 2020
    Applicant: Wallkill BioPharma, Inc.
    Inventors: Gerald F. SWISS, David KIEWLICH
  • GENETICALLY MODIFIED STEM CELLS
    Publication number: 20200283731
    Abstract: Described herein are human transgenic beta cells expressing fugetactic levels of CXCL12 to a subject in need thereof. Also described herein are beta cells comprising a transgene comprising a nucleic acid sequence encoding CXCL12.
    Type: Application
    Filed: March 20, 2020
    Publication date: September 10, 2020
    Inventors: Gerald F. Swiss, David Kiewlich
  • Treating diabetes with genetically modified beta cells
    Patent number: 10696950
    Abstract: Described herein are human transgenic beta cells expressing fugetactic levels of CXCL12 to a subject in need thereof. Also described herein are beta cells comprising a transgene comprising a nucleic acid sequence encoding CXCL12.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: June 30, 2020
    Assignee: Wallkill BioPharma, Inc.
    Inventors: Gerald F. Swiss, David Kiewlich
  • PLASMID VECTORS FOR EXPRESSION OF LARGE NUCLEIC ACID TRANSGENES
    Publication number: 20190390221
    Abstract: Provided herein, in certain embodiments, are plasmid expression vectors and methods of use of such vectors for either transient or stable integrated expression of transgenes in eukaryotic cells. The plasmid expression vectors provided herein are less than 3.6 kb in size and can accommodate large (>5 kb) polynucleotide insertions of transgenes and homology arms for stable integration.
    Type: Application
    Filed: November 2, 2017
    Publication date: December 26, 2019
    Inventor: David KIEWLICH
  • TREATING DIABETES WITH GENETICALLY MODIFIED BETA CELLS
    Publication number: 20190218518
    Abstract: Described herein are human transgenic beta cells expressing fugetactic levels of CXCL12 to a subject in need thereof. Also described herein are beta cells comprising a transgene comprising a nucleic acid sequence encoding CXCL12.
    Type: Application
    Filed: March 29, 2019
    Publication date: July 18, 2019
    Inventors: Gerald F. Swiss, David Kiewlich
  • TREATING DIABETES WITH GENETICALLY MODIFIED BETA CELLS
    Publication number: 20190100729
    Abstract: Described herein are human transgenic beta cells expressing fugetactic levels of CXCL12 to a subject in need thereof. Also described herein are beta cells comprising a transgene comprising a nucleic acid sequence encoding CXCL12.
    Type: Application
    Filed: September 28, 2018
    Publication date: April 4, 2019
    Applicant: Wallkill BioPharma, Inc.
    Inventors: David Kiewlich, Gerald F. Swiss
  • TREATING DIABETES WITH GENETICALLY MODIFIED BETA CELLS
    Publication number: 20190100730
    Abstract: Described herein are human transgenic beta cells expressing fugetactic levels of CXCL12 to a subject in need thereof. Also described herein are beta cells comprising a transgene comprising a nucleic acid sequence encoding CXCL12.
    Type: Application
    Filed: September 28, 2018
    Publication date: April 4, 2019
    Applicant: Wallkill BioPharma, Inc.
    Inventors: Gerald F. Swiss, David Kiewlich
  • THERAPEUTIC PEPTIDE-EXPRESSING CELLS
    Publication number: 20160074483
    Abstract: Provided herein are cells for in vivo expression of therapeutic proteins or peptides, methods of making and using the same.
    Type: Application
    Filed: April 11, 2014
    Publication date: March 17, 2016
    Applicant: Infinite Cells, LLC
    Inventor: David Kiewlich